Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019

Phytother Res. 2021 Oct;35(10):5417-5426. doi: 10.1002/ptr.7172. Epub 2021 Jun 10.

Abstract

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first occurred in China in December 2019 and subsequently spread all over the world with cardiovascular, renal, and pulmonary symptoms. Therefore, recognizing and treating the cardiovascular sign and symptoms that caused by coronavirus disease 2019 (COVID-19) can be effective in reducing patient mortality. To control the COVID-19-related cardiovascular symptoms, natural products are considered one of the promising choices as complementary medicine. Scientists are struggling to discover new antiviral agents specific to this virus. In this review, the natural products for management of cardiovascular symptoms of COVID-19 are categorized into three groups: (a) natural products with an impact on angiotensin II type 1 receptor; (b) natural products that inhibit angiotensin-converting enzyme activity; and (c) natural products that mimic adenosine activity. All these natural products should undergo clinical investigations to test their efficacy, safety, and toxicity in the treatment of cardiovascular symptoms of COVID-19. This article summarizes agents with potential efficacy against COVID-19-related cardiovascular symptoms.

Keywords: ACE inhibitor; COVID-19; angiotensin II type 1 receptor; cardiovascular disease; mimic adenosine; natural products.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors
  • Antiviral Agents / therapeutic use
  • Biological Products* / therapeutic use
  • COVID-19*
  • Humans
  • SARS-CoV-2

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antiviral Agents
  • Biological Products